Your daily source for AI news, tools reviews, and practical guides to artificial intelligence
OpenAI has introduced sandbox execution capabilities to its Agents SDK, enabling enterprise teams to deploy automated AI workflows with improved governance, security, and reliability. This update addresses previous challenges in balancing flexibility, control, and risk in production AI systems.
Converge Bio, an AI-focused drug discovery startup, has closed a $25 million Series A funding round led by Bessemer Venture Partners, attracting investments from prominent figures at Meta, OpenAI, and Wiz.
A significant backend vulnerability in the web admin dashboards of one of India’s largest pharmacy chains led to the exposure of thousands of online orders, underscoring the growing cybersecurity challenges in healthcare and retail sectors.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with support from prominent executives at Meta, OpenAI, and Wiz.
Converge Bio, an AI-powered drug discovery startup, has successfully raised $25 million in a Series A funding round led by Bessemer Venture Partners, with support from key executives at Meta, OpenAI, and Wiz.
Anthropic introduces Claude for Healthcare, enabling secure access to personal health data and advancing AI’s role in medical understanding, following OpenAI’s lead with ChatGPT Health.
Following OpenAI’s launch of ChatGPT Health, Anthropic introduces Claude for Healthcare, enabling secure connection to personal health data through Apple Health integration.
OpenEvidence, a leading medical information database, has doubled its valuation since October, securing a new funding round led by Thrive Capital and DST Global despite increasing competition from AI model developers.
SAP and Fresenius are joining forces to create a sovereign AI platform designed to securely process health data within clinical environments. This initiative addresses critical governance challenges in healthcare AI deployment, aiming to establish a compliant, integrated ecosystem that safeguards data sovereignty while enhancing patient care.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with additional investments from executives at Meta, OpenAI, and Wiz. This capital injection aims to accelerate the development of innovative therapies using artificial intelligence.